Population differences in vaccine response (POPVAC)-2: the impact of environmental exposures and selected interventions on waning of vaccine-induced immune responses
Lead Research Organisation:
London School of Hygiene & Tropical Medicine
Department Name: UNLISTED
Abstract
"Vaccines are a key weapon against infectious diseases which continue to have major detrimental impacts on health and development in in low-income countries (LICs). However, the effectiveness of some vaccines is reduced in tropical LICs and in rural vs urban settings. For example, the TB vaccine, BCG, provides 80% protection in some temperate countries, but 0% in some tropical settings.
A potential explanation for this phenomena includes exposure to parasites so to further understanding we will compare the vaccine responses for Ugandan adolescents among three groups: (1) urban-dwellers participating in our Entebbe Mother and Baby Study birth cohort who have low parasite exposure; (2) island communities where over 80% have schistosomiasis (a parasitic worm infection); (3) rural communities with high malaria exposure, where over 50% of school-children unknowingly have malaria. We will also look at how parasitic infections interact with other viral or bacterial infections (“transkingdom” effects) and how these indirect effects impact the immune system.
Finally, we will use statistical approaches to explore how the urban-rural environment, parasites, ""transkingdom"" effects and immune responses interrelate to determine vaccine responses. This fundamental information will contribute to the development of suitable vaccines for populations living in tropical LIC settings and inform public health policy to improve effectiveness of vaccine programmes."
A potential explanation for this phenomena includes exposure to parasites so to further understanding we will compare the vaccine responses for Ugandan adolescents among three groups: (1) urban-dwellers participating in our Entebbe Mother and Baby Study birth cohort who have low parasite exposure; (2) island communities where over 80% have schistosomiasis (a parasitic worm infection); (3) rural communities with high malaria exposure, where over 50% of school-children unknowingly have malaria. We will also look at how parasitic infections interact with other viral or bacterial infections (“transkingdom” effects) and how these indirect effects impact the immune system.
Finally, we will use statistical approaches to explore how the urban-rural environment, parasites, ""transkingdom"" effects and immune responses interrelate to determine vaccine responses. This fundamental information will contribute to the development of suitable vaccines for populations living in tropical LIC settings and inform public health policy to improve effectiveness of vaccine programmes."
Technical Summary
We propose that parasite infections contribute substantially to population differences in vaccine response; and that their effects are mediate We will test this hypothesis through four linked objectives among Ugandan adolescents. An immunisation programme comprising relevant live and inert vaccines will be given over one school year, with primary endpoints one month postimmunisation. A secondary endpoint at one year will assess response waning. 1. We will compare vaccine response profiles in urban adolescents (low parasite burden) with two rural cohorts, chosen for high schistosomiasis and high malaria prevalence. 2. We will establish whether current parasite infections have causal effects using individually-randomised, placebocontrolled interventions targeting the dominant infection in each rural cohort. Sample sizes will be robust, powered to detect vaccine response differences of 0.14log10 between study arms (modest effects compared to preliminary data). 3. We will assess herpesvirus-specific antibodies (Luminex), viral loads (droplet digital PCR) and cellular responses (ELISpot); and microbial translocation (MT; PCR for bacterial 16s ribosomal DNA, ELISA for lipopolysaccharide and other biomarkers). Markers of viral activation and MT will be related to parasite exposures and vaccine outcomes. 4. We will investigate pre-immunisation immunological characteristics using simple biomarkers and cell phenotyping, and with in-depth studies (including by mass cytometry) in smaller, representative groups; and link findings to both parasite exposures and vaccine outcomes. Our data will be integrated using causal mediation analyses to determine how urban-rural environment, parasites, "transkingdom" effects and immune responses relate to determine vaccine responses partly by "transkingdom" pathways (activation of herpesviruses; intestinal translocation of microbial products), and ultimately by pre-immunisation immune characteristics of the host.
Organisations
- London School of Hygiene & Tropical Medicine (Lead Research Organisation)
- Uganda National Expanded Programme on Immunisation (Collaboration)
- University of Manchester (Collaboration)
- Moderna (Collaboration)
- University of York (Collaboration)
- Wellcome Trust (Collaboration)
- Ministry of Health, Uganda (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Uganda Christian University (Collaboration)
- Leiden University Medical Center (Collaboration)
- Center of Medical Research Lambaréné (Collaboration)
- Texas Tech University Health Sciences Center (Collaboration)
- MRC/UVRI Uganda Research Unit on AIDS (Collaboration)
- Uganda Virus Research Institute (Collaboration)
Publications


Natukunda A
(2022)
The effect of helminth infection on vaccine responses in humans and animal models: A systematic review and meta-analysis
in Parasite Immunology
Description | Characterization of protein and glycan epitopes recognised following controlled human infection with Schistosoma mansoni in an endemic population |
Amount | € 149,846 (EUR) |
Organisation | Sixth Framework Programme (FP6) |
Department | European and Developing Countries Clinical Trials Partnership |
Sector | Public |
Country | Netherlands |
Start | 08/2021 |
End | 08/2024 |
Description | Deciphering the role of baseline transcription profile in determining vaccine responses. |
Amount | £11,443 (GBP) |
Organisation | Medical Research Council (MRC) |
Department | MRC/UVRI and LSHTM Research Unit Uganda |
Sector | Academic/University |
Country | Uganda |
Start | 01/2024 |
End | 07/2024 |
Description | Innovations for vaccines against helminth infections (WORMVACS2.0) |
Amount | € 7,510,206 (EUR) |
Organisation | European Commission |
Sector | Public |
Country | European Union (EU) |
Start | 08/2023 |
End | 08/2028 |
Description | NIHR Global Health Groupon on vaccines for vulnerable people in Africa (VAnguard) |
Amount | £2,984,447 (GBP) |
Funding ID | NIHR134531 |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 08/2022 |
End | 02/2026 |
Description | Supplement to MRC Programme Grant, Population differences in vaccine response: the role, reversibility and mediators of immunomodulation by chronic parasitic infections |
Amount | £200,000 (GBP) |
Funding ID | MC_PC 21034 |
Organisation | United Kingdom Research and Innovation |
Sector | Public |
Country | United Kingdom |
Start | 04/2022 |
End | 04/2023 |
Description | Wellcome International Training Fellowship for Gyaviira Nkurunungi: "The impact of differential parasite exposure on immunological and metabolic predictors of vaccine response in the tropics" |
Amount | £296,299 (GBP) |
Funding ID | 224263/Z/21/Z |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2025 |
Title | Data supporting "Does schistosome or malaria exposure contribute to urban-rural differences in vaccine responses in Uganda? A causal mediation analysis using data from three linked randomised controlled trials." |
Description | This dataset comprises individual-level data from participants in the POPVAC series of three randomised controlled trials. POPVAC A was conducted among schoolchildren from Koome islands, Uganda (a schistosomiasis-endemic setting), POPVAC B was conducted among schoolchildren from Jinja district, Uganda (a malaria-endemic setting), POPVAC C was conducted among schoolchildren from Entebbe, Uganda (a lower infection prevalence setting). |
Type Of Material | Database/Collection of data |
Year Produced | 2024 |
Provided To Others? | Yes |
Impact | This dataset comprises individual-level data from participants in the POPVAC series of three randomised controlled trials. POPVAC A was conducted among schoolchildren from Koome islands, Uganda (a schistosomiasis-endemic setting), POPVAC B was conducted among schoolchildren from Jinja district, Uganda (a malaria-endemic setting), POPVAC C was conducted among schoolchildren from Entebbe, Uganda (a lower infection prevalence setting). |
URL | https://datacompass.lshtm.ac.uk/id/eprint/3761 |
Title | Data supporting "The effect of intensive praziquantel treatment on vaccine-specific responses among schoolchildren in Ugandan schistosomiasis-endemic islands: results of the POPVAC A randomised, controlled trial" |
Description | This dataset comprises individual-level data from participants in the POPVAC A randomised controlled trial. POPVAC A was an open-label randomised controlled trial of intensive versus standard intervention against Schistosoma mansoni among schoolchildren (9-17 years) in Koome islands, Uganda (ISRCTN60517191). The aim of the trial was to comprehensively address the hypothesis that Schistosoma mansoni infection causes suppression of responses to unrelated vaccines and that this effect can be reversed by intensive treatment with praziquantel. The trial population was selected to comprise children at intense risk of exposure to Schistosoma mansoni infection in a "hot-spot", island setting in Lake Victoria, Uganda. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of intensive treatment of Schistosoma mansoni on immune response to vaccines with different characteristics. |
Type Of Material | Database/Collection of data |
Year Produced | 2024 |
Provided To Others? | Yes |
Impact | This dataset comprises individual-level data from participants in the POPVAC A randomised controlled trial. POPVAC A was an open-label randomised controlled trial of intensive versus standard intervention against Schistosoma mansoni among schoolchildren (9-17 years) in Koome islands, Uganda (ISRCTN60517191). |
URL | https://datacompass.lshtm.ac.uk/id/eprint/3758 |
Title | Data supporting "The effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on vaccine-specific responses among schoolchildren in rural Uganda: results of the POPVAC B randomised, controlled trial" |
Description | This dataset comprises individual-level data from participants in the POPVAC B randomised controlled trial. POPVAC B was a randomised, double-blind, placebo-controlled trial of the effect of malaria IPT with dihydroartemisinin-piperaquine (DP) on vaccine responses among schoolchildren (9-17 years) in Jinja district, Uganda (ISRCTN62041885). The aim of the trial was to comprehensively address the hypothesis that malaria infection causes suppression of responses to unrelated vaccines and that this effect can be reversed at least partially, by monthly intermittent preventive treatment (IPT) of malaria in high-transmission settings. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of IPT of malaria on immune response to vaccines with different characteristics. |
Type Of Material | Database/Collection of data |
Year Produced | 2024 |
Provided To Others? | Yes |
Impact | Newly available database, likely to contribute to international collaborations on factors that determine vaccine response |
URL | https://datacompass.lshtm.ac.uk/id/eprint/3759 |
Title | Data supporting: "The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents: results of the POPVAC C randomised, controlled trial" |
Description | This dataset comprises individual-level data from participants in the POPVAC C randomised controlled trial. POPVAC C was an open-label randomised controlled trial of Bacillus Calmette Guérin (BCG) revaccination versus no BCG among schoolchildren in Entebbe, Uganda (ISRCTN10482904). The aim of the trial was to comprehensively address the hypothesis that revaccination with BCG might enhance responses to unrelated vaccines. A portfolio of vaccines, of potential benefit to the children and comprising live, inert, oral and parenteral, was provided to enable a comprehensive assessment and comparison of effects of BCG revaccination on immune response to vaccines with different characteristics. |
Type Of Material | Database/Collection of data |
Year Produced | 2024 |
Provided To Others? | Yes |
Impact | Newly available database, likely to contribute to international collaborations on factors that determine vaccine response |
URL | https://datacompass.lshtm.ac.uk/id/eprint/3760 |
Description | Arbovirology, UVRI |
Organisation | Uganda Virus Research Institute |
Department | Department of Arbovirology, Emerging and Re-emerging Infections |
Country | Uganda |
Sector | Public |
PI Contribution | We are conducting the POPVAC research programme, samples from which will be processed by the department of arbovirology at UVRI |
Collaborator Contribution | They will undertake yellow fever plaque reduction neutralisation tests. |
Impact | Not yet |
Start Year | 2020 |
Description | Dr Cecile Crosnier |
Organisation | University of York |
Department | Department of Biology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are working with Dr Cecile Crosnier on her MRC Career Development Award to extend Dr Moses Egesa's work "Epitope mapping of schistosome tegument and alimentary tract proteins in humans". |
Collaborator Contribution | Dr Crosnier has availed a library of recombinant parasite proteins for use in assays with samples from Schistosomiasis endemic populations to identify the targets of protective immunity. |
Impact | A large resource of recombinant parasite proteins to identify the targets of protective immunity |
Start Year | 2022 |
Description | Dr James Hewitson |
Organisation | University of York |
Department | Department of Biology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | James Hewitson |
Collaborator Contribution | With Dr Hewitson, we have applied and successfully obtained two grants from GCRF and one from the MRC. Dr Moses Egesa has been seconded as Post-doctoral Research Associate to the Hewitson Laboratory to study (1) in vivo anti-schistosome immune responses in endemic populations using humanised mouse models of schistosomiasis and (2) infection-induced changes in haematopoiesis. Dr Egesa underwent training in animal models of schistosomiasis, cutting-edge technologies (humanised mouse models) and specialised immunological techniques (e.g. confocal microscopy, multi-parameter flow cytometry) |
Impact | Dr Egesa completed accredited training for personnel working under the Animals (Scientific Procedures) Act 1986; EU Modules achieved: PIL AB (by The University of Newcastle) EU Modules achieved: PIL C (by The Royal Veterinary College) |
Start Year | 2019 |
Description | Edridah Tukahebwa, Narcis Kabatereine |
Organisation | Ministry of Health, Uganda |
Department | Vector Control Division |
Country | Uganda |
Sector | Public |
PI Contribution | These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications. We have worked with them on implementation of all our helminth related work in Uganda. |
Collaborator Contribution | These collaborators have expertise in the epidemiology, diagnosis and control of helminth infections. They also understand policy implications and applications. |
Impact | Numerous papers and presentations Stakeholders' meetings Grants |
Description | Helen McShane, Adrian Hill, Alex Mentzer |
Organisation | University of Oxford |
Department | Jenner Institute |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Collaboration on (1) genetic studies on the response to infant vaccines (on-going) (2) a trial investigating the impact of schistosomiasis on the response to candidate TB vaccine MVA85A (completed) (3) a trial of ChAdOx1 85A and MVA85A as a new regimen for boosting TB immunity in adolescents. We are conducting the trial in Uganda (about to start) |
Collaborator Contribution | For (1) the partners provide expertise in genetics For (2) and (3) the partners are providing the vaccine, as well as contributing expertise in TB vaccine trials |
Impact | Publications and conference presentations DPhil for Alex Mentzer (completed) Contributions to PhDs for Swaib Lule (completed), Anne Wajja (on-going) and Beatrice Nassanga (about to commence) |
Start Year | 2017 |
Description | Innovations for vaccines against helminth infections (WORMVACS2.0) |
Organisation | Center of Medical Research Lambaréné |
Country | Gabon |
Sector | Academic/University |
PI Contribution | The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines. |
Collaborator Contribution | The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias |
Impact | Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing. |
Start Year | 2023 |
Description | Innovations for vaccines against helminth infections (WORMVACS2.0) |
Organisation | Leiden University Medical Center |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines. |
Collaborator Contribution | The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias |
Impact | Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing. |
Start Year | 2023 |
Description | Innovations for vaccines against helminth infections (WORMVACS2.0) |
Organisation | Moderna |
Country | United States |
Sector | Private |
PI Contribution | The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines. |
Collaborator Contribution | The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias |
Impact | Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing. |
Start Year | 2023 |
Description | Innovations for vaccines against helminth infections (WORMVACS2.0) |
Organisation | Texas Tech University Health Sciences Center |
Country | United States |
Sector | Academic/University |
PI Contribution | The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world's most devastating and persistent NTDs. Samples sets and data derived from the CHI studies with Schistosoma mansoni conducted by our research team will be leveraged to contribute to WORMVACS2.0 objectives. Cellular and humoral immune assays will be performed at UVRI - the site of the trial where samples are stored. We have actively engaged stakeholders and communities regarding helminth infections and preventive measures such as vaccines. |
Collaborator Contribution | The partners will generate a central data dashboard of all incoming experimental (immunological) data used for target antigen and vaccine production platform selection; Select new helminth vaccine candidate targets by microarray IgG, IgM, IgA, IgE reactivity of sera/plasma obtained in human infection models; Down select helminth vaccine candidate targets by antibody type, quality and function; Prepare mRNA, OMV and plant-derived vaccines based on existing and new antigens; Demonstrate immunogenicity of vaccine candidates produced in each platform in mice; prepare laboratory scale vaccine formulation for evaluation in the rodent immunisation and challenge models for S. mansoni and N. americanus; prepare pre-clinical OMV vaccines, mRNA vaccines, vaccines antigens expressed in plants, undertake immunogenicity of vaccine candidates in mice; Assess S. mansoni vaccine candidates in the murine model of schistosomias |
Impact | Optimised early clinical/late preclinical vaccine candidates for S. mansoni (trematode, blood fluke) and N. americanus (intestinal nematode, hookworm) Bridged gaps in knowledge of human immunology of experimental and naturally acquired helminth infections, including protective immunity. Using a systems biology approach, molecular/immune signatures will be determined to serve as correlates of protection. Establish an effective pipeline of vaccine discovery and development including the implementation of innovative production platforms that allow rapid production, engineering and adaptation of helminth vaccine antigens for pre-clinical and clinical testing. |
Start Year | 2023 |
Description | MRC/UVRI Uganda Unit - London School of Hygiene & Tropical Medicine |
Organisation | MRC/UVRI Uganda Research Unit on AIDS |
Country | Uganda |
Sector | Public |
PI Contribution | I and my research team are based at the MRC/UVRI Unit. I lead a research programme there. In 2018 the Unit became a part of the London School of Hygiene and Tropical Medicine so this ceased to be a collaboration in the earlier sense of the word. |
Collaborator Contribution | The MRC/UVRI Unit hosts the research, providing facilities, administration and research support |
Impact | This collaboration has resulted in more than 80 research publications, several research grants, two Wellcome Trust funded and one EDCTP funded research capacity building grants, much training at undergraduate, Masters, PhD and post-doctoral level. |
Description | Maria Yazdanbakhsh; Meta Roestenberg |
Organisation | Leiden University Medical Center |
Country | Netherlands |
Sector | Academic/University |
PI Contribution | We are undertaking collaborations with LUMC department of parasitology on immuno-epidemiological effects of helminths, and on schistosomiasis vaccine development including controlled human infection models for schistosomiasis (CHI-S) In 2019 we developed a proposal for establishing the CHI-S in Uganda which the Wellcome Trust panel supported for funding. We are awaiting the award letter. |
Collaborator Contribution | The partners provide technical expertise, particularly in parasite immunology and |
Impact | PhD: co-supervision to completion of two fellows, Gyaviira Nkurunungi and Moses Egesa (both completed successfully in 2019). Publications and conference presentations. New grants for preparatory work on Sm-CHI |
Start Year | 2011 |
Description | Metabolic phenotypes and vaccine response |
Organisation | University of Manchester |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are collaborating with Prof. Richard Grencis ( University of Manchester) on work to understand the association between pre-vaccination metabolic phenotype and the post-vaccination response to a panel of 5 vaccines (BCG, HPV, Yellow Fever, Oral typhoid, Tetanus/Diphtheria) among adolescents participating in a set of Ugandan trials. In Uganda, we will extract metabolites from plasma samples, and send them to Manchester for liquid chromatography-mass spectrometry (LC-MS) to quantitate metabolites. Results will be returned to us in Uganda for high dimensional analysis. |
Collaborator Contribution | The Manchester team will conduct the LC-MS experiments. |
Impact | We have worked on a Material Transfer Agreement and a collaboration agreement with the Manchester team. |
Start Year | 2023 |
Description | MoH UNEPI programme |
Organisation | Uganda National Expanded Programme on Immunisation |
Country | Uganda |
Sector | Public |
PI Contribution | We are running the POPVAC trials which will provide EPI with information on the effects of parasitic infections on the response to widely used vaccines. |
Collaborator Contribution | The EPI programme is providing HPV vaccine for individuals in the POPVAC trials. As well, they are supporting us with training and advice. |
Impact | None as yet |
Start Year | 2018 |
Description | NIHR Global Health Group, VAnguard |
Organisation | Uganda Christian University |
Country | Uganda |
Sector | Academic/University |
PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
Collaborator Contribution | Partners are leading various work packages |
Impact | No outputs yet. |
Start Year | 2022 |
Description | NIHR Global Health Group, VAnguard |
Organisation | Uganda Virus Research Institute |
Country | Uganda |
Sector | Public |
PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
Collaborator Contribution | Partners are leading various work packages |
Impact | No outputs yet. |
Start Year | 2022 |
Description | NIHR Global Health Group, VAnguard |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
Collaborator Contribution | Partners are leading various work packages |
Impact | No outputs yet. |
Start Year | 2022 |
Description | NIHR Global Health Group, VAnguard |
Organisation | Wellcome Trust |
Department | KEMRI-Wellcome Trust Research Programme |
Country | Kenya |
Sector | Academic/University |
PI Contribution | This is a new Global Health Group which I lead together with Professor Pontiano Kaleebu, taking forward our work on optimising vaccine benefits for vulnerable populations in Africa. |
Collaborator Contribution | Partners are leading various work packages |
Impact | No outputs yet. |
Start Year | 2022 |
Description | Global Challenges & Opportunities for Vaccines |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | A workshop on the immunomodulating effects of helminth infection. |
Year(s) Of Engagement Activity | 2023 |
Description | Hypovax: connecting people to reverse vaccine hyporesponsiveness |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | A workshop on population differences in vaccine responses and how hyporesponsiveness could be addressed. |
Year(s) Of Engagement Activity | 2024 |
URL | https://hypovax.org/ |
Description | VAnguard Global Health Group Launch event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | An event engaging collaborators, community members and other stakeholders to initiate and plan for the NIHR Global Health Group, VAnguard |
Year(s) Of Engagement Activity | 2022 |
Description | WORMVACS consortium meeting |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Inaugural meeting of the WORMVACS-2 consortium |
Year(s) Of Engagement Activity | 2023 |
URL | https://linq-management.com/news/wormvacs-kickoff-meeting-in-leiden.html |